Lucira Health Past Earnings Performance
Past criteria checks 0/6
Lucira Health's earnings have been declining at an average annual rate of -93.1%, while the Medical Equipment industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 558.8% per year.
Key information
-93.1%
Earnings growth rate
-24.6%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 558.8% |
| Return on equity | -235.3% |
| Net Margin | -67.5% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Lucira Health reports early data for point of care chlamydia and gonorrhea assays
Sep 29Lucira COVID & Flu test gets emergency use authorization from Health Canada
Aug 11Lucira Health Sees Strong Revenue Growth But Needs More Cash
Mar 10Analysts' Revenue Estimates For Lucira Health, Inc. (NASDAQ:LHDX) Are Surging Higher
Nov 25
Is Lucira Health (NASDAQ:LHDX) In A Good Position To Invest In Growth?
Jun 29Lucira Health appoints medtech veteran Kevin Collins as CRO
May 28Health Canada issues 'authorization with conditions' for Lucira's COVID-19 test kit
Apr 26Revenue & Expenses Breakdown
How Lucira Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 212 | -143 | 57 | 41 |
| 30 Jun 22 | 193 | -44 | 52 | 46 |
| 31 Mar 22 | 179 | -38 | 39 | 45 |
| 31 Dec 21 | 93 | -65 | 31 | 40 |
| 30 Sep 21 | 32 | -74 | 26 | 39 |
| 30 Jun 21 | 17 | -59 | 16 | 34 |
| 31 Mar 21 | 5 | -49 | 11 | 28 |
| 31 Dec 20 | 0 | -37 | 6 | 25 |
| 30 Sep 20 | 0 | -22 | 4 | 19 |
| 31 Dec 19 | 0 | -8 | 2 | 11 |
Quality Earnings: LHDX.Q is currently unprofitable.
Growing Profit Margin: LHDX.Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if LHDX.Q's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare LHDX.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LHDX.Q is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (3.7%).
Return on Equity
High ROE: LHDX.Q has a negative Return on Equity (-235.31%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/04 19:35 |
| End of Day Share Price | 2023/10/04 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lucira Health, Inc. is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Derik de Bruin | BofA Global Research |
| David Sherman | LifeSci Capital, LLC |
| Brian Weinstein | William Blair & Company L.L.C. |